Marabelle A, Le DT, Ascierto PA, et al. - From the phase II KEYNOTE-158 study of pembrolizumab in patients with previously treated, advanced noncolorectal high microsatellite instability (MSI-H)/DNA mismatch repair (dMMR) cancer, researchers reported outcome data. Eligible patients received pembrolizumab 200 mg once every 3 weeks was administered for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal. Enrollment of 233 patients was performed; among these, 27 tumor types were represented, with endometrial, gastric, cholangiocarcinoma, and pancreatic cancers being the most common. Outcomes support anti–programmed death-1 therapy with pembrolizumab as clinically beneficial among these patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer. They observed an objective response rate of 34.3%; median progression-free survival of 4.1 months (95% CI, 2.4 to 4.9 months) and median overall survival of 23.5 months (95% CI, 13.5 months to not reached). One hundred fifty-one patients (64.8%) experienced treatment-related adverse events; grade 3 to 5 treatment-related adverse events occurred in 34 patients (14.6%) and grade 5 pneumonia occurred in one patient.